Insider filing · HALO
Jeffrey William Henderson
Director
profile →
Halozyme Therapeutics, Inc.
HALO · Healthcare · 39 filings in 24 months
ticker →
Jeffrey William Henderson sold $293K of Halozyme Therapeutics (HALO)
Executed Mar 3 2025, disclosed Mar 3 2025, the same day.
Value, as filed
$293K
5,000 sh across 2 lots
Executed
Mar 3 2025
the trade date, as filed
Disclosed
Mar 3 2025
0 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JHJeffrey William Henderson (Director) filed 5 Form 4 reports in the past 24 months (1 purchase, 4 sales), most often in Halozyme Therapeutics, Inc. (HALO). Across 1 priced purchase filing, the average 21-session return was -1.7% from execution and -1.7% from disclosure (delay-adjusted; derived). The largest single filing was $500K of HALO (10,000 sh × $50.01, as filed), executed Jan 6 2025.
The name
HALOHealthcare · Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in th…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Jeffrey William Henderson in HALO
HALOSALE
Halozyme Therapeutics, Inc.
$259K4,297 sh × $60.34
Exec Apr 28 2025
Filed Apr 28 2025 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. $220K
3,900 sh × $56.41
Exec Feb 3 2025
Filed Feb 4 2025 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. $500K
10,000 sh × $50.01
Exec Jan 6 2025
Filed Jan 7 2025 · 5:30 PM ET